Occurrence of acute nonlymphoblastic leukemia in two girls after treatment of recurrent, disseminated Langerhans cell histiocytosis

Pediatric Hematology and Oncology

Volumn 16, Issue 3, 1999, Pages 251-256

  Kager, L ^a   Heise, A ^a   Minkov, M ^a   Mobius D ^b   Kotte, W ^c   Schulte Overberg, U ^d   Henze, G ^d   Gadner, H ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b CARL THIEM KLINIKUM   (Germany)

^c Kinderklinik Stadtisches Krankhs ^*  (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute nonlymphoblastic leukemia; Langerhans cell histiocytosis; Outcome; Treatment

Indexed keywords

ALKYLATING AGENT; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; INTERCALATING AGENT; MERCAPTOPURINE; METHOTREXATE; STEROID; VINBLASTINE; VINCRISTINE;

ACUTE LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CASE REPORT; FEMALE; HISTIOCYTOSIS X; HUMAN; HUMAN TISSUE; INFANT; MYELODYSPLASTIC SYNDROME; PRESCHOOL CHILD; PROGNOSIS; REFRACTORY ANEMIA; SECOND CANCER;

BONE MARROW TRANSPLANTATION; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INFANT; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; RECURRENCE;

EID: 0032915082     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/088800199277317     Document Type: Article

References (19)

1. Egeler RM, Neglia J, Pucetti DM, et al. Association of Langerhans cell histiocytosis with malignant neoplasms. Cancer. 1993;71:865-873.
2. Egeler RM, Neglia JP, Arico M, et al. Acute leukemia in association with Langerhans cell histiocytosis. Med Pediatr Oncol. 1994;23:81-85.
3. Gadner H, Heitger A, Grois N, et al. A treatment strategy for disseminated langerhans cell histiocytosis. Med Pediatr Oncol. 1994;23:72-80.
4. Creutzig U, Bender-Götze C, Klingebiel T, et al. Vergleich der alleinigen Chemotherapie mit der allogenen Knochenmarkstransplantation in erster Vollremission bei Kindern mit akuter myeloischer Leukämie in den Studien AML-BFM-83 und AML-BFM-87. Klin Pädiatr. 1992;204:246-252.
5. Koscielniak E, Herbst M, Niethammer T, Treuner J. Verbesserung der lokalen Tumorkontrolle durch einen frühen und risikoadaptierten Einsatz der Radiotherapie bei primär nicht resektablen Rhabdomyosarkomen: Ergebnisse der CWS-81 und 86 Studien. Klin Pädiatr. 1994;206:269-276.
6. Hawkins MM, Kinnier Wilson LM, Stovall MA, et al. Epipodophyllotoxins, alkylating agents and radiation and risk of secondary leukemia after childhood cancer. BMJ. 1992;304:951-958.
7. Levine E, Bloomfield C. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol. 1992;19:47-84.
8. Pedersen-Bjegaard J, Philip P, Pedersen NT, et al. Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. Cancer. 1984;54:452-462.
9. Matsuzaki A, Inamitsu T, Watanabe T, et al. Acute promyelocytic leukemia in a patient treated with etoposide for Langerhans cell histiocytosis. Br J Haematol. 1994;86:887-889.
10. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risk. Med Pediatr Oncol. 1994;23:86-98.
11. Whitlock JA, Greer JP, Lukens JN. Epipodophyllotoxin-related leukemia. Cancer. 1991;68:600-604.
12. Ladisch S, Gadner H. Treatment of Langerhans cell histiocytosis: evolution and current approaches. Br J Cancer. 1994;70:41-46.
13. Gadner H. Etoposide in Langerhans cell histiocytosis. Pediatr Hematol Oncol. 1996;13:309-311.
14. Kantarjian HM, Keating MJ, Walters RS, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic and prognostic features. J Clin Oncol. 1986;4:1748-1757.
15. Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood. 1985;65:1364-1372.
16. Kitabayashi T, Sekiguchi N, Yanai M, et al. Acute promyelocytic leukemia following etoposide-based combination chemotherapy for Letterer-Siewe disease. Jpn J Pediatr Haematol. 1992;6:232-236.
17. Horibe K, MatsushitaT, Shin-Ichiro N, et al. Acute promyelocytic leukemia with t (15;17) abnormality after chemotherapy containing etoposide for Langerhans cell histiocytosis. Cancer. 1993;72:3723-3726.
18. Haupt R, Fears TR, Rosso P, et al. Increased risk of secondary leukemia after single-agent treatment with etoposide for Langerhans cell histiocytosis. Pediatr Hematol Oncol. 1994;11:499-507.
19. Haupt R, Fearf TR, Heise A, et al. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans cell histiocytosis in Italian and Austrian-German populations. Int J Cancer. 1997;71: 9-13.